page 55, line 9, change "Gene Pulser" to --GENE PULSER--.

page 57, line 2, change "Alamar Blue" to --ALAMAR BLUE--.

page 59, line 8, change "Superdex" to --SUPERDEX--.

page 61, line 9, change "Sepharose" to --SEPHAROSE--.

page 62, line 13, change "Alamar Blue" to --ALAMAR BLUE--.

line 16, change "Fluoroscan" to --FLUOROSCAN--.

page 63, line 15, change "vital" to --living--.

page 65, line 7, change "Amplify" to --AMPLIFY--;

line 23, change "Excell" to --EXCELL--; and

line 27, change "Culturebags" to --CULTUREBAGS--.

page 66, line 4, change "Minitan" to --MINITAN--.

page 67, line 21, change "Block Ace" to --BLOCK ACE--.

page 68, line 12, change "AB Complex" to --AB COMPLEX--.

page 74, line 21, change "Superscript" to --SUPERSCRIPT--.

page 75, line 15, change "Ampli-Tag" to --AMPLITAQ--.

page 76, line 6, change "Gene Clean" to --GENECLEAN--.

page 78, line 26, change "sequensing" to --sequencing--.

page 79, line 7, change "sequensing" to --sequencing--;

line 8, change "Autosequenser" to --Autosequencer--;

line 18, change "Sequensing" to --Sequencing--; and

line 21, change "sequensed" to --sequenced--.

page 80, line 6, change "Poly(A) Quick" to --POLY(A)
QUICK--; and

line 9, change "First Strand" to --FIRST STRAND--.

page 82, line 6, change "Gene Clean" to --GENECLEAN--.

page 84, line 16, change "sequensing" to --sequencing--; and

line 24, change "sequensing" to --sequencing--.

page 86, line 21, change "Superscript" to --SUPERSCRIPT--.

page 87, line 10, change "Amplitaq" to --AMPLITAQ--.

page 89, line 17, change "Gene Pulser" to --GENE PULSER--.

page 98, line 22, change "Pepset" to --PEPSET--; and

line 27, change "Maxisorp" to --MAXISORP--.

page 100, line 21, change "of LSHKVYMRNS and VYMRNSKYPQ" to --consisting of residues 1 to 10 and residues 5 to 14 of SEQ ID NO: 31--; and

line 24, after the sequence insert --(SEQ ID NO:31)--.

IN THE CLAIMS:

Kindly renumber the claims submitted with the Preliminary Amendment dated September 19, 1997 (claims 1-104) as claims 57-160. Following renumbering, please amend claims 57-68, 79-81 and 160 as follows:

57. (Amended) A monoclonal antibody or active fragment thereof that [which] specifically reacts with a Fas ligand, [or an active fragment thereof,] wherein said antibody or fragment thereof inhibits [against the inhibitory activity] apoptosis more [is higher] than [that of] a control Fas-Ig chimera molecule.